Arvinas (NASDAQ:ARVN) outlined upcoming clinical milestones across its oncology and neurology pipeline during its third-quarter 2026 earnings call, while reporting lower operating expenses and a cash runway projected into the second half of 2028. President and CEO Randy Teel said the company is pri
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.
Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC)
Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings
On August 4, Arvinas Inc. (NASDAQ:ARVN) reported second-quarter 2026 financial results and a corporate update that doubled as one of the more consequential updates in the company’s history. The clinical-stage biotech disclosed the first-ever FDA approval of a PROTAC, a heterobifunctional protein degrader, alongside a licensing deal that hands off commercial duties to another drugmaker. […]
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock inc
This is the newest page. Registered accounts read further back.